Kandu’s At-Home Brain-Computer Interface Offers a ‘Can-Do’ Approach to Stroke Rehabilitation
Kandu CEO Leo Petrossian explains how IpsiHand — an EEG headset and robotic brace that translates thought into movement — aims to reach the millions of chronic stroke survivors that conventional rehabilitation has left without options.
Medtech Insight - July 21, 2026

AAIC: Blood-Based Alzheimer’s Biomarkers Gain Ground
The Alzheimer’s Association International Conference (AAIC) showed that p-tau217 blood tests are rapidly becoming the "gold standard" for diagnosis – and possibly even prognosis.
In Vivo - July 21, 2026

DePuy Synthes Buys Expandable-Cage Maker Expanding Innovations Ahead Of J&J Spinoff
J&J's DePuy Synthes has acquired expandable-cage maker Expanding Innovations for undisclosed terms, a tuck-in aimed at the fastest-growing slice of the spine market — and one more move to sharpen the orthopedics unit ahead of a planned spin-off or a reported $20bn-plus sale.
Medtech Insight - July 21, 2026

German Committee Backs Rx-To-OTC Switch Of Topical Prednisolone
Germany's SVA switch committee has recommended releasing topical prednisolone from prescription control, one of three switch applications it backed at its July 21 meeting.
HBW Insight - July 21, 2026

Pharma’s Rare Earth Moment: China’s Leverage Puts The US And India On Notice
China's pharma leverage is real and goes beyond KSMs all the way up the value chain to biologics, trials, and synthetic DNA, say experts. The US and India face a supply chain reckoning, with one industry veteran suggesting that “informal choke-toolkits” are being formalized.
Scrip - July 21, 2026

Cosentyx Close To Peak $8bn Sales For Novartis
CEO Vas Narasimhan tells Scrip about the "new energy" driving the decade-old brand which is still the Swiss drugmaker’s biggest seller by some distance.
Scrip - July 21, 2026

Agios Shelves Tebapivat In Sickle Cell, Weeks After MDS Exit
Agios’s shares took a hit after it scrapped tebapivat in sickle cell disease, the drug’s second failure in under two months, with mitapivat now its only shot in sickle cell.
Scrip - July 21, 2026

Stock Watch: Johnson & Johnson Gets No Credit For Weathering The Stelara Cliff
Johnson & Johnson delivered 6.6% second-quarter sales growth and raised full-year guidance, yet its stock fell nearly 3% on the day. Concerns over medical devices, talc litigation and future loss of blockbuster drug exclusivity seemed to be overweight in investors’ assessment of the company.
Scrip - July 21, 2026

J&J On How Imaavy Can Compete In The FcRn Field
J&J's immunology medical affairs leader Mark Graham talks to Scrip how the company is sequencing indications for the FcRn inhibitor Imaavy.
Scrip - July 21, 2026

Henlius Advances Darzalex And Opdivo Biosimilar Trials
Henlius has dosed the first patients across four biosimilar programs this summer, advancing daratumumab, nivolumab, cetuximab, and ipilimumab candidates in the US and China.
Generics Bulletin - July 21, 2026

Inspection Findings Highlight Hurdles Facing Alvotech’s Launch Plans
An FDA inspection has found continuing quality-system deficiencies at Alvotech’s Reykjavik plant, where manufacturing issues have already delayed several US biosimilar applications.
Generics Bulletin - July 21, 2026

Canadian Generics Face Tougher Path Around Dosing Regimen Patents
Canada’s Supreme Court has upheld Janssen’s Invega Sustenna dosing patent, blocking Pharmascience’s generic and setting a new test focusing on whether claims constrain physicians’ clinical judgment.
Generics Bulletin - July 21, 2026

Dr Reddy’s Bottleneck Stalls Aspen’s Canadian Semaglutide Ambitions
Aspen has won Canadian approval for generic injectable semaglutide, but API supply problems at Dr Reddy’s have delayed commercialization and could weaken its early-mover advantage.
Generics Bulletin - July 21, 2026

Lupin Spins Off, Licenses Two Oncology Assets In Renewed Funding Attempt
Lupin has spun off a PRMT5 inhibitor and an SOS1 asset, licensing them to Kaveri Therapeutics in return for a 82.2% stake. Initially supported by seed funding from Lupin, the US-based entity will seek to raise funds in a renewed attempt at taking oncology assets to global clinical trials
Scrip - July 21, 2026

Clinical Trial Complexity Is Reshaping Evidence Collection
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Scrip - July 21, 2026

Chinese Anti-Infectives Specialist Trinomab Grosses $148m In Shanghai IPO
Trinomab becomes the first biotech to wrap up an IPO on the Shanghai STAR Market this year, raking in new funds to support its pipeline of novel anti-infective antibodies.
Scrip - July 21, 2026

Podcast: How ElevateBio Is Betting On Every Gene Editing Modality At Once
ElevateBio's CSO Amy Pooler on why no single gene editing modality will dominate, and how AI-designed enzymes and smarter delivery could finally unlock large gene therapies.
In Vivo - July 21, 2026

FDA Tightens Stance On Terumo’s RelayPro: Return The Devices, Don’t Use Them
The FDA has told clinicians to return the recalled RelayPro thoracic stent-grafts to the maker rather than keep using them cautiously — a tightening from earlier notices.
Medtech Insight - July 21, 2026

The Biggest Launches In Pharma History Are Increasingly Forecasts, Not Records
Evaluate data on the biggest drug launches ever shows actual sales topping the table at year three – led by COVID-19 vaccines – before forecasts take over at years five and 10, almost entirely incretin assets. Counted as one franchise, Lilly's tirzepatide approaches $72bn by year 10.
In Vivo - July 21, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: J&J ups guidance; Gilead’s acquisition strategies; Bayer breakup rumors; Biogen’s Alzheimer’s results; and an interview with Lilly’s blood test pioneer.
Scrip - July 21, 2026

CorTec’s BCI Shows Early Promise In Stroke Rehab With 8 to 12 Point FMA-UE Gains
CorTec’s implantable BCI system has shown early safety and functional gains in three stroke patients, with Fugl-Meyer (FMA-UE) upper extremity improving by 8-12 points. Rivals Neurolutions, Mobia Medical and Enspire leverage EEG, VNS and DBS technologies respectively also use FMA-UE as benchmark.
Medtech Insight - July 21, 2026